Kancera AB (publ)

Stockholm Stock Exchange KAN.ST

Kancera AB (publ) Goodwill for the year ending December 31, 2023

Kancera AB (publ) Goodwill is NA for the year ending December 31, 2023. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Kancera AB (publ) Goodwill for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Kancera AB (publ) Goodwill for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Kancera AB (publ) Goodwill for the year ending December 31, 2019 was USD 0.00.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

Stockholm Stock Exchange: KAN.ST

Kancera AB (publ)

CEO	Mr. Peter Selin
IPO Date	Feb. 25, 2011
Location	Sweden
Headquarters	Karolinska Institutet Science Park
Employees	5
Sector	Healthcare
Industries Clinical Trials Biotechnology Pharmaceuticals Vaccines

Description

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.

Key trends

Past 5 years